OBJECTIVE: The aim of the study was to assess different outcome measures in a cohort of ambulant boys with Duchenne muscular dystrophy (DMD) over 12 months in order to establish the spectrum of possible changes in relation to age and steroid treatment. METHODS: The study is a longitudinal multicentric cohort study. A total of 106 ambulant patients with DMD were assessed using the 6-minute walk test (6MWT) and North Star Ambulatory Assessment (NSAA) at baseline and 12 months. Clinical data including age and steroid treatment were collected. RESULTS: During the 12 months of the study, we observed a mean decline of 25.8 meters in the 6MWT with a SD of 74.3 meters. On NSAA, the mean decline was 2.2 points with a SD of 3.7. Not all the boys with DMD in our cohort showed a decline over the 12 months, with young boys showing some improvement in their 6MWT and NSAA scores up to the age of 7. NSAA and the 6MWT had the highest correlation (r = 0.52, p < 0.001). CONCLUSIONS: This study provides longitudinal data of NSAA and 6MWT over a 12-month period. These data can be useful when designing a clinical trial.
OBJECTIVE: The aim of the study was to assess different outcome measures in a cohort of ambulant boys with Duchenne muscular dystrophy (DMD) over 12 months in order to establish the spectrum of possible changes in relation to age and steroid treatment. METHODS: The study is a longitudinal multicentric cohort study. A total of 106 ambulant patients with DMD were assessed using the 6-minute walk test (6MWT) and North Star Ambulatory Assessment (NSAA) at baseline and 12 months. Clinical data including age and steroid treatment were collected. RESULTS: During the 12 months of the study, we observed a mean decline of 25.8 meters in the 6MWT with a SD of 74.3 meters. On NSAA, the mean decline was 2.2 points with a SD of 3.7. Not all the boys with DMD in our cohort showed a decline over the 12 months, with young boys showing some improvement in their 6MWT and NSAA scores up to the age of 7. NSAA and the 6MWT had the highest correlation (r = 0.52, p < 0.001). CONCLUSIONS: This study provides longitudinal data of NSAA and 6MWT over a 12-month period. These data can be useful when designing a clinical trial.
Authors: Jia Li; Tom R Geisbush; Glenn D Rosen; Jennifer Lachey; Aaron Mulivor; Seward B Rutkove Journal: Muscle Nerve Date: 2014-06 Impact factor: 3.217
Authors: Seward B Rutkove; Kush Kapur; Craig M Zaidman; Jim S Wu; Amy Pasternak; Lavanya Madabusi; Sung Yim; Adam Pacheck; Heather Szelag; Tim Harrington; Basil T Darras Journal: Ann Neurol Date: 2017-05-04 Impact factor: 10.422
Authors: Craig M Zaidman; Jim S Wu; Kush Kapur; Amy Pasternak; Lavanya Madabusi; Sung Yim; Adam Pacheck; Heather Szelag; Tim Harrington; Basil T Darras; Seward B Rutkove Journal: Ann Neurol Date: 2017-05-04 Impact factor: 10.422
Authors: Bhaskar Roy; Basil T Darras; Craig M Zaidman; Jim S Wu; Kush Kapur; Seward B Rutkove Journal: Clin Neurophysiol Date: 2019-02-12 Impact factor: 3.708
Authors: Ishu Arpan; Rebecca J Willcocks; Sean C Forbes; Richard S Finkel; Donovan J Lott; William D Rooney; William T Triplett; Claudia R Senesac; Michael J Daniels; Barry J Byrne; Erika L Finanger; Barry S Russman; Dah-Jyuu Wang; Gihan I Tennekoon; Glenn A Walter; H L Sweeney; Krista Vandenborne Journal: Neurology Date: 2014-08-06 Impact factor: 9.910
Authors: Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan Journal: Muscle Nerve Date: 2013-05-16 Impact factor: 3.217
Authors: Ishu Arpan; Sean C Forbes; Donovan J Lott; Claudia R Senesac; Michael J Daniels; William T Triplett; Jasjit K Deol; H Lee Sweeney; Glenn A Walter; Krista Vandenborne Journal: NMR Biomed Date: 2012-10-09 Impact factor: 4.044